New hair loss drug for women enters final testing phase

NCT ID NCT07303322

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether an oral solution called N1087 can help women with female pattern hair loss regrow hair. About 372 women aged 18 to 60 will receive either N1087 or a placebo daily for 24 weeks. The study measures changes in hair density and thickness using scalp photos.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

N1087 (oral solution)

What this could lead to

If it works, this could offer a new daily treatment option to help women with thinning hair regrow thicker hair.

What could go wrong

This is an early Phase 3 trial, so results are not yet known. The drug may not work better than placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEMALE PATTERN HAIR LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••